Management of CMML with TET2 Mutation

Risk Stratification and Prognostic Implications

The presence of a TET2 mutation in CMML does not fundamentally alter the treatment approach, as management should be stratified primarily by disease phenotype and blast percentage, with TET2 mutations being present in approximately 60% of CMML patients and associated with favorable prognosis when present without concurrent ASXL1 mutations 1, 2
Risk stratification should utilize molecularly-integrated prognostic models such as the Mayo Molecular Model (MMM), CMML-specific prognostic scoring system (CPSS-Mol), or Groupe Français des Myélodysplasies (GFM) model, which incorporate molecular information beyond just TET2 status 3

For MD-CMML with low blast count, the American College of Hematology recommends initiating supportive therapy aimed at correcting cytopenias, focusing on symptom reduction and quality of life improvement 1, 2
For MD-CMML with low blast count, the European Hematology Association suggests using erythropoietic-stimulating agents for severe anemia (hemoglobin <10 g/dL) after measuring serum erythropoietin levels 1, 2
For MD-CMML with high blast count (CMML-2), the National Comprehensive Cancer Network recommends integrating supportive therapy with hypomethylating agents (azacitidine or decitabine) to reduce blast counts and improve survival 1, 2
For MP-CMML with low blast count, the American Society of Hematology recommends initiating cytoreductive therapy with hydroxyurea to control proliferative myelomonocytic cells and reduce organomegaly 1, 2
For MP-CMML with high blast count, the European Society for Medical Oncology suggests administering blastolytic therapy with polychemotherapy followed by allogeneic stem cell transplantation when feasible 1, 2

Therapy should be started when one of the following criteria is met: severe anemia (hemoglobin <10 g/dL), peripheral blood blasts >5%, platelet count ≤50 × 10⁹/L, WBC count ≥30 × 10⁹/L, immature granulocytes ≥10% in peripheral blood, extramedullary manifestations, or symptomatic splenomegaly 3, 4

Allogeneic HSCT remains the only potentially curative treatment option and should be considered for intermediate to high-risk patients who are eligible, according to the American Society of Hematology 1, 2
Reduced-intensity conditioning (RIC) transplant has demonstrated improved outcomes compared to myeloablative conditioning, particularly relevant for the typical CMML patient presenting in the 7th decade of life, as recommended by the European Group for Blood and Marrow Transplantation 4, 1, 2

For patients not receiving treatment, the International Working Group recommends obtaining full blood count one month after diagnosis to assess hematologic stability, and monitoring with full blood count and clinical examination every three months for MD-CMML and monthly for the first three months for MP-CMML 3, 1
For patients on treatment, the International Working Group suggests applying IWG 2006 response criteria for MDS in MD-CMML patients and IWG 2009 response criteria for myelofibrosis in MP-CMML patients, with responses lasting at least 4 weeks to be considered true treatment responses 3, 2